Are you interested in cancer research? Have you been affected by cancer in some form or fashion? If you’re like most people, then you’ve probably been affected by this disease either directly or indirectly. Millions of people have lost their lives fighting this dangerous disease, but the 21st century has introduced some of the best cancer-fighting medications to date. Gone are the days of amputations and radical surgeries. This new wave of medications are targeted in a sense, and they are able to destroy cancer cells without harming any of the good cells in the body. This is where Dr. Clay Siegall comes into the picture, and he has grown into an industry-icon.
President, Founder and CEO is only a few of Dr. Clay Siegall’s titles. Seattle Genetics is his biotech-oncology company, and it is a leader of the field. Siegall started his career well-over 30 years ago. One of his first high-profile positions came via Senior Research Investigator for Bristol Myers Squibb. In addition to that, he has worked with the all-exclusive National Institute of Health. Seattle Genetics was founded back in 1998, and it has grown dramatically throughout the years. The company specializes in the development and in the commercialization of antibody-drug conjugates. These are some of the most technologically advanced medications for fighting cancer, and they have saved lives at a much higher rate than previous cancer medications. Siegall spends a lot of time developing the drugs, which provides great assurance for the patients in the end.
This company earns money in multiple ways such as the selling of its own proprietary drugs, through production partnerships as well as from the licensing of its technologies. The future is looking mighty bright for Seattle Genetics, for Dr. Clay Siegall and for cancer patients that are located around the world.